Sort by:
Need a comprehensive medical report on "A"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome
Not Applicable
Not yet recruiting
- Conditions
- Cascade TestingLynch SyndromeDecision Making
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 185
- Registration Number
- NCT07106359
- Locations
- 🇺🇸
UAB, Birmingham, Alabama, United States
Safety and Efficacy of ONT01 in Lupus
Not Applicable
Not yet recruiting
- Conditions
- Lupus Nephritis (LN)Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVLupus Nephritis - World Health Organization (WHO) Class IIILupusSLESystemic Lupus ErythematosusSystemic Lupus Erythematosus (Disorder)
- Interventions
- Drug: ONT01 is a small molecule CD11b modulator.
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 61
- Registration Number
- NCT07107659
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
Standard Second-line Therapy With Toripalimab and Ongericimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
Not Applicable
Not yet recruiting
- Conditions
- Advanced Colorectal Cancer
- Interventions
- Drug: Ongericimab + Toripalimab + Bevacizumab + FOLFOXDrug: Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Shanghai Pudong Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT07106034
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, Shanghai, China
A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
- Conditions
- Rectal Cancer, Adenocarcinoma
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 250
- Registration Number
- NCT07107815
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
Not Applicable
Not yet recruiting
- Conditions
- Aortic Valve Stenosis and InsufficiencyCoronary Artery Disease(CAD)Transcatheter Aortic Valve Replacement (TAVR)
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 700
- Registration Number
- NCT07107568
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- HCC - Hepatocellular CarcinomaMelanomaPancreatic Ductal AdenocarcinomaCholangiocarcinomaHNSCCEndometrial CancerTesticular CancerNSCLC (Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT07106827
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Study to Investigate the Effectiveness, Safety, and Tolerability of MAG200 Solution for Intra-articular Injection Compared With Placebo in Participants Aged 35 to 75 Years of Age With Symptomatic Osteoarthritis of the Knee.
Not Applicable
Not yet recruiting
- Conditions
- Knee Osteoarthristis
- Interventions
- Other: PlaceboBiological: allogeneic human adipose-derived mesenchymal stem cells
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Magellan Stem Cells
- Target Recruit Count
- 573
- Registration Number
- NCT07106229
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
Not Applicable
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Nimotuzumab+Adebrelimab+Chemotherapy
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 68
- Registration Number
- NCT07105592
- Locations
- 🇨🇳
Fudan University, Shanghai, Shanghai, China
Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2
Not Applicable
Recruiting
- Conditions
- Healthy
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 32
- Registration Number
- NCT07105514
- Locations
- 🇩🇰
Optic Neuritis Clinic, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark
Effect of Static vs. Conversational AI-Generated Messages on Colorectal Cancer Screening Intent: a Randomized Controlled Trial
Not Applicable
Completed
- Conditions
- Colorectal Cancer Control and Prevention
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 915
- Registration Number
- NCT07107152
- Locations
- 🇺🇸
Participants are recruited online via Prolific, Philadelphia, Pennsylvania, United States